Immune Checkpoint Inhibitors in Small Cell Lung Cancer: A Partially Realized Potential

A Randomized Non-Comparative Phase 2 Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients with Small Cell Lung Cancer: Results from the IFCT-1603 Trial

(2019) Jean-Louis Pujol et al.   Journal of Thoracic Oncology

LBA1_PRNivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study

(2019) T K Owonikoko et al.   ANNALS OF ONCOLOGY

Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line – Results from the prospective German TLK cohort study

(2019) Claus-Christoph Steffens et al.   LUNG CANCER

Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)

(2018) Shirish M. Gadgeel et al.   Journal of Thoracic Oncology

Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.

(2018) Hyun Cheol Chung et al.   JOURNAL OF CLINICAL ONCOLOGY

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

(2018) Leora Horn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032

(2018) Neal Ready et al.   Journal of Thoracic Oncology

Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study

(2017) Patrick A. Ott et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer

(2016) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†

(2012) M. Reck et al.   ANNALS OF ONCOLOGY

Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data

(2012) Antonio Rossi et al.   JOURNAL OF CLINICAL ONCOLOGY

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

(2012) Martin Peifer et al.   NATURE GENETICS